Date: 2013-03-07
Type of information: Services contract
Compound: custom genome-engineered iPS cells
Company: Cellectis (France) Stemgent (USA)
Therapeutic area:
Type agreement: collaboration
services
Action mechanism:
Disease:
Details: Cellectis bioresearch, a subsidiary of Cellectis Group, and Stemgent have concluded collaboration agreement to provide research services that combines mRNA reprogramming technology and genome engineering. he partnership marries Cellectis bioresearch\'s leadership in genome engineering with Stemgent\'s expertise in cellular reprogramming. Stemgent\'s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral, non-integrating, clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine, drug discovery, and basic research.
Financial terms:
Latest news:
